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Considering the threat of antimicrobial resistance and the difficulties it entails in treating 
infections, it is necessary to cross borders and approach infection management in an 
integrated, multidisciplinary manner. We propose the antimicrobial, infection prevention 
and diagnostic stewardship model comprising three intertwined programs: antimicrobial, 
infection prevention and diagnostic stewardship, involving all stakeholders. The focus is a 
so-called ‘theragnostics’ approach. This leads to a personalized infection management plan, 
improving patient care and minimizing resistance development. Furthermore, it is important 
that healthcare regions nationally and internationally work together, ensuring that the 
patient (and microorganism) transfers will not cause problems in a neighboring institution. 
This antimicrobial, infection prevention and diagnostic stewardship model can serve as a 
blue print to implement innovative, integrative infection management.
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Antimicrobial resistance is a growing public health threat, signaling the beginning of a postantimi-
crobial era [1]. Infections caused by multidrug-resistant organisms (MDROs) are associated with a 
significant deterioration of clinical outcomes. This includes an increased risk of mortality and mor-
bidity, and it is associated with an increase in costs [2]. Recently, consensus has been achieved that the 
global community should act to limit these emerging problems as much as possible [1–3]. Emergence 
of antimicrobial resistance is strongly correlated with incorrect antimicrobial prescribing patterns and 
the lack of consistent diagnostic procedures to identify the pathogens involved, whether viral, bacte-
rial or fungal. While antimicrobial medication has undoubtedly reduced mortality due to infections, 
resistance to these drugs renders them ineffective. To address these issues, healthcare institutions are 
implementing Antimicrobial Stewardship Programs (ASPs) to manage antimicrobial usage with the 
goal of improving patient outcomes, minimizing collateral damage and reducing the incidence of 
MDRO infections. They aim at treating patients according to the pathogens involved, based on a diag-
nostic strategy that ultimately keeps control on increasing expenditures in healthcare [4–6]. Participating 
in ASPs is mainly seen as a task of clinical microbiologists and/or infectious diseases specialists, 
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together with (hospital) pharmacists. However, 
as patients move within the hospital, many more 
stakeholders are involved: bedside doctors, nurses 
and boards of directors and diagnostic laboratory 
directors who are responsible for providing finan-
cial resources. Furthermore, patients are not only 
moving within one particular hospital but also 
between different hospitals and other healthcare 
institutions as part of a comprehensive healthcare 
network. Therefore, infection management in a 
specific (part of an) institution will affect patients 
throughout the entire network [7,8]. Infection 
management is thus a responsibility of all stake-
holders involved in this network. Additionally, 
recent developments in cross-border patient care 
have even extended these current healthcare net-
works to different countries, following the new 
EU directive on patients’ rights in cross-border 
healthcare (directive 2011/24/EU) [9–11]. Since 
microbes will not adhere to any borders made by 
humans (i.e., departments, institutions or coun-
tries), we are forced to think and act in the same 
manner and closely collaborate in developing and 
implementing strategies that prevent patients from 
being colonized or infected with MDRO.
Cohen et al., recently advocated the use of a 
‘multifaceted ‘omics’ approach’, to decrease the 
turn-around time of microbiological diagnos-
tics [12]. We agree with this vision, but think this 
solution is part of a bigger picture. New diag-
nostic tools are important, but so is the inter-
pretation and translation of the results into the 
day-to-day infection management. This requires 
cooperation of everyone involved in one large 
network.
We therefore strongly advocate collabora-
tion of several disciplines within and between 
involved (healthcare) institutions, regionally and 
internationally, thereby crossing multiple bor-
ders. The main challenge is to develop an inte-
grated system of not only ASPs, but also Infection 
Prevention Stewardship Programs (ISP) as well 
as Diagnostic Stewardship Programs (DSP), 
combined in an ‘AID stewardship model’. These 
combined stewardship programs should be con-
sultancy-based systems, involving and support-
ing stakeholders within the healthcare network 
(Figure 1), aiming at optimizing (laboratory) 
diagnostics, interpreting results and initiating 
correct and appropriate antimicrobial therapy 
(Figure 2). Furthermore, they act at the network 
level, aiding in taking the right infection control 
measures in order to provide a safe environment 
for patients and healthcare workers. Ultimately, 
this should also lead to more cost-effective 
healthcare in the mid-to-long term. In this view 
much can be learned from the theragnostic 
approach in cancer therapy, a holistic approach 
combining genetics, nuclear medicine and labo-
ratory diagnostics guiding to adjust therapy [13].
Modern and rapid diagnostics should focus 
on individual patient care. Thus, from the view-
point of individual patients, rapid identification 
of the causative agent, initiating optimal therapy 
and preventing the spread of highly infectious 
and pathogenic micro-organisms are crucial. A 
more classical approach divides the world into 
microbes, host and population and leads to a 
division between diagnostics, patient care and 
public health. This is particularly clear in coun-
tries where microbiology laboratories are located 
far away from patient care and even from clini-
cal expertise. A stringent patient-oriented and 
personalized approach is needed where clinical 
consequences are directly dependent on timely 
generated microbiological (molecular) diagnos-
tics. Consequently, in the field of antimicrobial 
therapy, appropriate and timely diagnostics need 
to be initiated before starting therapy. This will 
improve infection management on patient level 
by avoiding inadequate therapy and thus prevent-
ing collateral damage such as toxicity, driving 
antimicrobial resistance and spread of (MDR) 
organisms within the healthcare network.
To attain this goal of a theragnostic approach 
to infection management, we have developed a 
cross-border AID stewardship program, which 
is already partly implemented. Many are con-
tributing to this integrated infection manage-
ment system, each with a specific background 
and training. To facilitate this innovative and 
integral approach of infection management, 
the implementation of novel eHealth systems 
is essential as well as input of social sciences 
to take into account the influence of behav-
ior [14–16]. Our developed program is an exam-
ple of how the AID stewardship model could 
be implemented and can provide a blueprint or 
inspiration for others in the field of infection 
management and beyond.
Antimicrobial stewardship
Within the AID stewardship model, the ASP is 
based on the American (SHEA/IDSA) guide-
lines and the Dutch and German guidelines for 
ASPs [17–21]. It represents a program comprising 
various building blocks as shown in the mas-
ter scheme (Figure 2). Key components of this 
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Figure 1. Multistakeholder platform of the 
antimicrobial, infection prevention and 
diagnostic stewardship model. Pyramid 
platform showing the interdisciplinary 
stakeholder connections between the ASP, ISP 
and DSP within the antimicrobial, infection 
prevention and diagnostic stewardship model. 
This model represents the complexity of the 
patients (green for low complex, orange for 
intermediate complex and red for high complex) 
that corresponds with number of patients and 
treating staff (width of the pyramid) and the 
experience level of the treating staff (height of 
the pyramid). The more complex a patient, the 
more he/she requires experienced specialists 
from multiple disciplines supplemented with 
correct, on-time performed diagnostics and 
eHealth tools. This, together, is needed to 
adequately deal with the specific infectious 
problems, whereby the complexity of the patient 
is not a fixed label, but a continuous changing 
state which varies over time. 
ASP: Antimicrobial Stewardship Program; 
DSP: Diagnostic Stewardship Program; 
ISP: Infection Prevention Stewardship Program.
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scheme are: appropriate and timely microbio-
logical diagnostics, calculated empirical ther-
apy based on up-to-date regional/local epide-
miology, close cooperation with the pharmacy 
department [20–22] and continuous clinical and 
proper financial outcome evaluations [6].
Our ASP program within the AID steward-
ship model especially focuses on a day-2 bundle 
with intervention taking place on the second day 
of antimicrobial therapy through face-to-face 
case audits by the antimicrobial stewardship-
team (A-Team) [22,23]. Triggered by an email-
alert, an A-Team member will go to the ward 
and discuss the antimicrobial therapy with the 
bedside physician with a goal to improve and 
streamline the therapy using the by-then avail-
able diagnostics. This A-Team comprises clini-
cal microbiologists, infectious diseases specialists 
and hospital pharmacists. They are supported 
by designated, trained doctors (link doctors) 
and nurses (link nurses) on every hospital ward. 
This bundle intervention aims for proactive dis-
cussions with prescribing doctors, leading to a 
consensus-driven intervention optimizing anti-
microbial therapy, depending on patient status 
and the available diagnostic results. Early results 
are highly positive, both clinically and finan-
cially [23,24]. This highly interactive, face-to-face 
approach is dependent on the complexity of the 
patient’s condition, whereby the more complex 
patients demand more sophisticated diagnostics 
and the expertise of (senior) specialists from dif-
ferent disciplines (Figure 1). This implies cross-
ing traditional borders between disciplines and 
combining the knowledge and expertise of the 
treating physicians and the A-Team members 
optimally for the benefit of the individual patient 
and the healthcare institution.
An important, and in practice often some-
what neglected, area is the optimization and per-
sonalization of therapy. This should take into 
account basic patient factors such as prelimi-
nary diagnosis, compartment of the infection, 
bodyweight, pharmacokinetic aspects (includ-
ing organ dysfunction and current volume of 
distribution, among others), pharmacodynamic 
characteristics of the drugs (e.g., killing activity, 
among others) and characteristics of the micro-
organisms (most relevantly the MIC). An inte-
gration of these factors can be performed using 
pharmacokinetic and pharmacodynamic (PK/
PD) data and models. This approach can be used 
to optimize empiric therapy (based on popula-
tion data for both patients and microorganisms), 
as well as personalizing therapy for individual 
patients over time. Especially for the latter 
aspect, appropriate therapeutic drug monitor-
ing (TDM) needs to be implemented. When 
integrating all available data, both optimizing 
the effect of antimicrobial therapy as well as lim-
iting collateral damage (toxicity and emergence 
of resistance) can be addressed.
Before starting the development and imple-
mentation of an ASP, it is important to assess 
the already implemented activities, as well as the 
specific requirements of the healthcare institu-
tion. Therefore, we have developed an ASP 
maturity model approach, which can be used for 
such an assessment. This will help tailor an ASP 
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Figure 2. Master scheme antimicrobial, infection prevention and diagnostic stewardship model. 
Flow chart that depicts the path of care of a patient from top to bottom, surrounded by (several of) 
the building blocks of the three different, but supplemental, stewardship programs and how they 
are intertwined. Notice the overlap, thereby showing the necessity of all three stewardship programs 
and integrative nature of the model. 
AID: Antimicrobial, infection prevention and diagnostic; ASP: Antimicrobial Stewardship Program; 
DSP: Diagnostic Stewardship Program; ISP: Infection Prevention Stewardship Program.
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program to the specific needs of the healthcare 
institution making it easier to integrate within 
an overarching model such as the AID model [4]. 
Furthermore, preparing for a future with more 
cross-border patient movements, it is vital to 
also facilitate cross-border capacity building 
for the development of A-Teams in the clinical 
practice. This fosters collaboration and knowl-
edge transfers between science, health and small/
medium enterprises ultimately leading to new 
innovative eHealth technologies from an end-
user involvement perspective [14–16]. For the sup-
port of activities of the A-Teams, we already have 
developed several of these eHealth tools, notably 
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mobile applications and automatic e-mail alerts, 
in order to facilitate easy access to diagnostic and 
therapeutic data, which significantly improved 
the decision-making processes [25,26]. However, 
more eHealth tools are available, most notably 
different clinical discussion support systems 
(CDSSs), which can aid and support the pre-
scriber and/or the A-Team in optimizing anti-
microbial therapy [27]. It is important to create 
an ICT-structure that can be used to transfer 
patient data safely and confidently. This is not 
yet implemented for microbiological diagnostics. 
However, within our healthcare region this is for 
example already achieved for radiographic data.
infection prevention stewardship
It is vital that infection control and preven-
tion measures are integrated into this unified 
program to improve overall infection manage-
ment. Without the proper infection prevention 
measures, other interventions such as ASPs and 
DSPs will not yield the optimal effect. Within 
the AID stewardship model, infection preven-
tion stewardship entails early detection and close 
surveillance of MDROs, as well as an adequate 
rapid reaction to every possible transmission 
(Figure 2). This task is dependent on easy access 
to rapid microbiological diagnostics for both 
direct patient care and surveillance purposes. 
Therefore, our units of infection control and pre-
vention and medical microbiology (bacteriology, 
virology, mycology and parasitology) are organ-
ized within one single department for maximal 
collaboration and cooperation and work together 
closely with the internal medicine department 
and the hospital pharmacy. Together, they 
are responsible for, for example, hand hygiene 
guidelines and audits, isolation measures and 
patient-specific consultations and hospital-wide 
infrastructure (e.g., contribution to in-hospital 
guidelines for infections and the antimicrobial 
formularium). The success story of the contain-
ment of MRSA within The Netherlands by a 
search-and-destroy strategy is an example of the 
substantial positive effect of close cooperation 
between clinical microbiology and infection pre-
vention specialists [28]. This applies to bacteria as 
well as viruses where similar screening programs 
are also beneficial [29–31]. Continuous commu-
nication with other ISP consultants within the 
healthcare network and developing and updat-
ing unified guidelines at the regional level is 
important [8,32,33]. In ISP, the use of eHealth 
technology, developed in a multidisciplinary 
environment by medical experts together with 
eHealth experts, has considerable potential to 
facilitate these work processes [14,16]. For exam-
ple, it has been shown that web-based guidelines 
are suboptimally used by nurses [34]. With the aid 
of user-centered and persuasive eHealth systems, 
the adherence to guidelines improved and errors 
in using them reduced significantly [34]. These 
systems were developed as part of MRSA-net [35] 
and EurSafety Health-net [36] in the Dutch-
German Euregio, exemplifying the potential of 
eHealth for ISPs [25,37].
Diagnostic stewardship
To provide the optimal therapy for individual 
patients but also for infection control and pre-
vention purposes, it is essential that state-of-
the-art diagnostics are performed timely, before 
initiating antimicrobial therapy. Diagnostics 
must be appropriate for the individual patient, 
target all pathogens causing acute infections and 
detect colonization and/or infection. Helping 
individual physicians in selecting and interpret-
ing diagnostic tests on the appropriate clinical 
specimens is the major goal of diagnostic stew-
ardship. To be most effective, these diagnostic 
tests should provide relevant clinical data as soon 
as possible, but for sure within the first hours of 
admission (viral) or the first 24–48 h of admis-
sion (bacterial and fungal). Molecular diagnos-
tics can largely meet these requirements. With 
new point-of-care (or point-of-impact) assays 
(e.g., testing different biomarkers) becoming 
available, the turnaround time for an increas-
ing number of viral and bacterial/fungal patho-
gens can be reduced to less than 2 h, support-
ing clinical decision-making. An important 
issue is furthermore supporting a noninfectious 
differential diagnosis for certain conditions if 
appropriate diagnostics rapidly yield negative 
results. Similar as the theragnostics approach in 
oncology, this should ultimately lead to a more 
personalized infection management plan for 
the patient, whereby diagnostics, therapy and 
infection prevention are integrated.
The use of innovative methods (e.g., next-gen-
eration sequencing) is an exciting evolving field 
within clinical microbiology and infection con-
trol and is advocated by more as one of the solu-
tions for antimicrobial resistance [12]. It fits within 
the theragnostic approach to treatment and, 
therefore, innovative point-of-impact technolo-
gies and real-time sequencing tools are already 
put into use within the AID stewardship model 
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and will be fully implemented in standard daily 
care in the near future [31,38]. We expected that 
also novel comprehensive diagnostic tools will 
provide results much faster and more accurately, 
as already shown to be the case in combined viro-
logical and bacteriological diagnostics (e.g., mul-
tiplex molecular tests) [39,40]. This can provide the 
basis for better and more personalized therapy 
for patients, contributing to an optimized use of 
antimicrobials, surveillance and infection control, 
all leading to a more theragnostic approach of 
infection management. Of course, that does not 
disqualify the use of conventional, culture-based 
diagnostics like conventional blood, urine sputum 
and other cultures combined with susceptibility 
testing. Bacterial cultures for example are still an 
effective and relatively cheap diagnostic tool for 
the diagnosis of infections/colonization. In addi-
tion, they are the only means to assist in storage 
and typing of specific isolates. However, the turn-
around times of these tests often are too long to be 
useful in the early stages of treatment. Especially 
in regions where diagnostic facilities are situated 
far away from the actual point of patient care, 
logistics can negatively impact the turnaround 
time. Making these tools available in the near 
proximity of patient care will significantly reduce 
turnaround times.
With the implementation of rapid point-of-
impact technologies, subsequent rapid decision-
making will be beneficial for the optimal use 
of resources (for instance bed management and 
isolation room capacity). These diagnostic assays 
and next-generation diagnostics are mostly 
based on molecular technologies and are there-
fore more expensive compared with classical 
culture-based methodology. They are however 
faster, delivering results within hours, thereby 
enabling a theragnostic approach for infection 
management. A proper cost–effectiveness study 
can provide the validation for the implementa-
tion of these tests. However, from a managerial 
point of view and to support health economical 
decision-making, the so-called ‘€hr concept’ can 
easily make turnaround times visible in relation 
to the overall costs (such as costs for unnecessary 
isolation). By multiplying costs (€) and turna-
round time (h), it provides a quick, understand-
able figure, assuming that quality remains high 
and therefore equals one. This provides the basis 
of the diagnostics needed for the AID steward-
ship (Figure 3).
integrated stewardship: crossing multiple 
borders
In our view, infection management cannot be 
adequately performed by one single doctor, by 
one medical specialty, by one hospital or even by 
one country. Infection management in health-
care networks is based on an interdisciplinary 
and inter-regional approach (Figure 1). Movement 
of patients within and between healthcare 
institutions entails movement of microorgan-
isms within and to other institutes as well. For 
this reason, we have developed an integrated 
AID stewardship model in close cooperation 
with healthcare institutions and diagnostic 
laboratories within the region.
Due to the regional nature, this program is 
part of a larger Euregional collaboration between 
The Netherlands and Germany, initially started 
on a relatively small scale with the MRSA-net 
project. It has, in the meanwhile, been extended 
to the EurSafety Health-net project [36] cover-
ing the complete Dutch–German border region 
(>8 million inhabitants). Over the years, this 
resulted in an intense collaboration of more than 
115 acute care hospitals, more than 200 long-
term care facilities and a large array of healthcare 
institutions, working together on infection man-
agement. Optimizing patient care and infection 
control by building networks of stakeholders, 
knowledge transfer and consolidating the best of 
both worlds has always been the primary focus. 
Within this cross-border network, the focus lies 
on ASP, ISP and DSP. In this approach, eHealth 
contributes significantly to the different goals in 
these projects. Among many other results, this 
has led to tools for clear and easy presentation 
of MRSA protocols [17,34,37], but also middleware 
solutions to improve molecular diagnostics like 
FlowG [41]. In order to facilitate the imple-
mentation of the AID stewardship model, the 
EurSafety Health-net project has led to various 
other applications that were developed and can 
be used on-site by infection experts, healthcare 
providers and patients, implementing eHealth in 
daily cross-border practice [15,25,27,40].
conclusion
In our view, managing antimicrobial infections 
can only be achieved by a holistic approach 
based on the theragnostic principles as exempli-
fied by the AID stewardship model, with the 
implementation of timely (innovate) diagnostics, 
woven into the treatment management plan and 
infection prevention. When combining ASP, 
ISP and DSP, one is able to target the complete 
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Figure 3. €hr concept within the antimicrobial, 
infection prevention and diagnostic 
stewardship model. A diagram showing a 
top-view of Figure 1. Diagnostics should be 
present to provide an integrative and effective 
stewardship program such as antimicrobial, 
infection prevention and diagnostic. From a 
managerial point of view, the effectiveness of 
these diagnostics can be described with the 
€hr concept, visualizing the most important 
aspects: turnaround time (h) and costs (€), 
assuming that quality remains high and 
therefore equals one. 
ASP: Antimicrobial Stewardship Program; 
DSP: Diagnostic Stewardship Program; 
ISP: Infection Prevention Stewardship Program.
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healthcare network, which can be supported by 
health economics, social sciences, technological 
sciences and by using eHealth technologies.
This technology is crucial to support mul-
tidisciplinary and cross-border infection man-
agement, to share knowledge and to support 
healthcare workers and infection specialists with 
easy accessible and user-friendly instructions for 
stewardship programs. First, to share knowledge 
and thoughts about integrated AID stewardship 
in healthcare; second to provide systems to sup-
port staff in implementing stewardship programs 
in daily work; third to guide the implementation 
process related to local situations and global 
guidelines for safe work and reduction of antimi-
crobial resistance rates. The University of Twente 
(Enschede, The Netherlands) develops the eco-
system for novel technologies that address these 
questions. In the EurSafety Health-net project, 
several technologies have already been developed 
to support the administration of antimicrobi-
als [25], to improve surveillance of infections [26], 
and to implement stewardship programs [4]. These 
technologies are created in co-design with the end 
users (e.g., nurses, physicians and infection pre-
vention specialists). Key stakeholders in the cross-
border network need to be involved and contrib-
ute appropriately to the system to guarantee the 
model will be effectively implementable [15,42,43].
Within this model, it is vital to work together 
and to utilize expertise of various stakeholders 
and organizations to intervene at various time 
points in infection management. The three dif-
ferent stewardship aspects are highly intertwined 
and must be implemented adequately. Especially 
in regions with higher resistance rates, this inte-
gration is even more important in order to control 
the situation and work toward an improvement. 
The AID stewardship model is in that respect 
generally applicable because the main focus point 
is the integration of the three stewardship pro-
grams. The specific actions performed within 
these programs depend on the setting of the 
healthcare institution. Implementing a monova-
lent ASP, as advocated in several countries, is of 
limited use without the implementation of appro-
priate and more sophisticated diagnostics close 
patient care and vice versa. Since hospitals are part 
of comprehensive healthcare networks, it is not 
helpful if one hospital has implemented a com-
plete stewardship program, but the hospital next 
door has not made proper, similar arrangements.
Therefore, we encourage stakeholders to cross 
borders and organize patient-centered infection 
management in a theragnostic, multifaceted, 
multidisciplinary, inter-regional approach to 
counteract antimicrobial resistance problems. 
In this manner, smaller institutions without 
extensive resources can benefit from academic 
centers and these centers in turn benefit with 
the referral of patients. The AID stewardship 
model that we are enrolling is an example 
of such an approach, which could serve as a 
blueprint in the field of infection management 
worldwide.
Future perspective
An increasing amount of microbiology data 
is becoming available for clinicians to be used 
when treating patients, including genomic data 
and information on the potential pathogen. 
Furthermore, it will get easier to link already 
existing data from different databases to provide 
a real-time up-to-date overview of the patient 
and his treatment (such as MIC values and 
PD/PK information), that clinician can use. 
Clinical decision support systems are already 
becoming available that can help the clinician 
in interpreting this increasing amount of data. 
These programs are expected to become smarter 
and more comprehensive in the near future. All 
Future Microbiol. (2015) 11(1)100
PersPective Dik, Poelman, Friedrich et al.
future science group
this should hopefully lead to a situation where 
personalized treatment can be started right away 
or at least within the first hours after a patient 
enters the hospital with a (suspected) infectious 
problem. This will be facilitated by the use of 
novel diagnostic technologies (e.g. third/fourth 
generation sequencing and spectroscopy) and 
smart decision support systems. ASPs can uti-
lize this data to ensure optimal treatment at all 
times, acting upon PK/PD data in real time. 
This should limit the amount of inadequately 
prescribed antimicrobials, thereby minimiz-
ing resistance pressure and collateral damage 
to patients. It would optimize the complete 
infection management process, thus providing 
better and more (cost-)efficient patient care. 
Furthermore, these data could facilitate opti-
mized infection prevention within the health-
care region, by providing real-time patient and 
pathogen characteristics to all involved health-
care institutions. It is vital that stakeholders 
cross borders and start collaborating as soon as 
executive summary
 ●  Antimicrobial resistance is a growing worldwide public health threat and the result of suboptimal infection 
management.
 ●  We advocate more collaboration between all stakeholders within and between (healthcare) institutions, regionally and 
internationally.
 ●  The here proposed antimicrobial, infection prevention and diagnostic (AID) stewardship model is an example of such a 
strong collaboration.
 ●  The AID stewardship model is a theragnostic approach to infection management addressing antimicrobial, infection 
prevention and Diagnostic Stewardship Programs.
Antimicrobial stewardship
 ●  Key components are appropriate, timely microbiological diagnostics, calculated empirical therapy, close cooperation 
with the pharmacy department and continuous clinical and financial outcome evaluations with a focus on a day-2 
bundle of audit/feedback.
 ●  Pharmacokinetic and pharmacodynamic data are used to further improve and personalize antimicrobial treatment.
infection prevention stewardship
 ●  Infection Prevention Stewardship Program entails early detection and close surveillance of multidrug-resistant 
organisms, as well as an adequate rapid reaction to every possible transmission.
 ●  Continuous communication within the healthcare region and unification of guidelines is important.
Diagnostic stewardship
 ●  For personalized treatment and for infection control and prevention purposes, state-of-the-art diagnostics should be 
performed timely, before initiating antimicrobial therapy.
 ●  Diagnostics must be appropriate and detect colonization and/or infection within 24–48 h of admission.
integrated stewardship: crossing multiple borders
 ●  Infection management in healthcare networks should be based on an interdisciplinary and inter-regional approach of 
all stakeholders.
 ●  The AID stewardship model supports this approach and is part of a larger Euregional collaboration between The 
Netherlands and Germany.
 ●  This international collaboration led to multiple eHealth applications that facilitate the AID stewardship model.
conclusion & future perspective
 ●  Managing antimicrobial infections can only be achieved by a holistic approach based on the theragnostic principles as 
exemplified by the AID stewardship model.
 ●  eHealth technology is crucial to support multidisciplinary, cross-border infection management.
 ●  We encourage stakeholders to cross borders and organize patient-centered infection management in a theragnostic, 
multifaceted, multidisciplinary, inter-regional approach to counteract antimicrobial resistance problems.
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possible, in order to provide an integrative infec-
tion management such as the proposed integra-
tive stewardship model. By an integrative stew-
ardship approach, such as our proposed AID 
model, healthcare institutions will immediately 
be streamlining the infection management pro-
cess. This will form a foundation of stakeholder 
collaborations that are necessary to utilize the 
upcoming flow of data and integrate these data 
in day-to-day patient care.
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